Accelerating Antibody Drug Development With Subdomain-Specific Affinity Chromatography
Affinity purification platforms such as Protein A or L are well-established in the manufacturing process of therapeutic monoclonal antibodies. However, with the development of engineered modalities such as bi-specific antibodies, fragments and Fc-fusion proteins, challenges in the downstream process of these molecules arise.
Affinity chromatography resins, specifically developed to bind antibody-subdomain regions, can provide an alternative solution in the purification process of these new formats. Thereby, advancing the commercial production of new antibody therapeutics.
Download this poster to discover a solution that can:
- Perform high target purity in a single step
- Provide unique VHH screening technology to determine final resin properties
- Be suitable for cGMP manufacturing processes